Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated:  7/19/2016
Clinical Trial Site
mi
from
Pittsburgh, PA
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated: 7/19/2016
Clinical Trial Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated:  7/19/2016
Clinical Trial Site
mi
from
Plano, TX
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated: 7/19/2016
Clinical Trial Site
mi
from
Plano, TX
Click here to add this to my saved trials
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated:  7/19/2016
Clinical Trial Site
mi
from
Falls Church, VA
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated: 7/19/2016
Clinical Trial Site
mi
from
Falls Church, VA
Click here to add this to my saved trials
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated:  7/19/2016
Clinical Trial Site
mi
from
Norfolk, VA
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated: 7/19/2016
Clinical Trial Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated:  7/19/2016
Clinical Trial Site
mi
from
Anderlecht,
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Status: Enrolling
Updated: 7/19/2016
Clinical Trial Site
mi
from
Anderlecht,
Click here to add this to my saved trials
A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
A Randomized Open-label, Multiple-dose, Crossover Study Evaluatig The Pharmacodynamics And Pharmacokinetics Of Filgrastim Hospira Compared To Us-approved Neupogen (Registered) Following Subcutaneous Administration To Healthy Volunteers
Status: Enrolling
Updated:  7/20/2016
SeaView Research Inc.
mi
from
Miami, FL
A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
A Randomized Open-label, Multiple-dose, Crossover Study Evaluatig The Pharmacodynamics And Pharmacokinetics Of Filgrastim Hospira Compared To Us-approved Neupogen (Registered) Following Subcutaneous Administration To Healthy Volunteers
Status: Enrolling
Updated: 7/20/2016
SeaView Research Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Emory Healthcare - Children's Center
mi
from
Atlanta, GA
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Emory Healthcare - Children's Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Dunwoody Pediatrics & Children's Healthcare of Atlanta
mi
from
Dunwoody, GA
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Dunwoody Pediatrics & Children's Healthcare of Atlanta
mi
from
Dunwoody, GA
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Fort Wayne Medical Oncology and Hematology
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Clinical Research Facility
mi
from
Fort Wayne, IN
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Boston Children's Hospital
mi
from
Boston, MA
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Henry Ford Health System
mi
from
Detroit, MI
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Children's Hospital at Montefiore
mi
from
Bronx, NY
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Hudson Valley Oncology Hematology
mi
from
Hawthorne, NY
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Hudson Valley Oncology Hematology
mi
from
Hawthorne, NY
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Weill-Cornell Medical College
mi
from
New York, NY
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Arthur James Cancer Hospital
mi
from
Columbus, OH
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Arthur James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Driscoll Children's Hospital
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Seattle Children's Hospital
mi
from
Seattle, WA
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Fox Valley Hematology
mi
from
Osh Kosh, WI
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Fox Valley Hematology
mi
from
Osh Kosh, WI
Click here to add this to my saved trials
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated:  7/25/2016
Royal Adelaide Hospital
mi
from
North Tce. Adelaide,
aHUS Observational Long Term Follow-Up
An Observational, Multi-Center, Multi-National, Long Term Follow-Up Study of Atypical Hemolytic Uremic Syndrome (aHUS) Patients Treated With Eculizumab in a Prior Clinical Study
Status: Enrolling
Updated: 7/25/2016
Royal Adelaide Hospital
mi
from
North Tce. Adelaide,
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Los Robles Hospital and Medical Center
mi
from
Thousand Oaks, CA
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Los Robles Hospital and Medical Center
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Florida Cancer Specialists
mi
from
Ft. Myers, FL
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Florida Cancer Specialists
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
National Capital Clinical Research Consortium
mi
from
Bethesda, MD
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
National Capital Clinical Research Consortium
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Leading Edge Research, PA
mi
from
Arlington, TX
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Leading Edge Research, PA
mi
from
Arlington, TX
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Children's Hospital Oakland
mi
from
Oakland, CA
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Childrens National Medical Center
mi
from
Washington,
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
University of Miami Batchelor Children's Research Center
mi
from
Miami, FL
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
University of Miami Batchelor Children's Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Children's Memorial Hospital
mi
from
Chicago, IL
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Louisiana State University Children's Medical Center
mi
from
New Orleans, LA
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Louisiana State University Children's Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
University of Michigan
mi
from
Ann Arbor, MI
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Duke University Medical Center Children's Hospital
mi
from
Durham, NC
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Duke University Medical Center Children's Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Medical University of South Carolina
mi
from
Charleston, SC
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Texas Transplant Institute
mi
from
San Antonio, TX
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials